Previous 10 | Next 10 |
"Sloth makes all things difficult, but industry all easy; and he that riseth late must trot all day, and shall scarce overtake his business at night; while laziness travels so slowly, that poverty soon overtakes him .”― Benjamin Franklin Karyopharm Therapeutics ( KPTI ) re...
Image source: The Motley Fool. Karyopharm Therapeutics Inc (NASDAQ: KPTI) Q3 2019 Earnings Call Nov 4, 2019 , 8:30 a.m. ET Operator Continue reading
Karyopharm Therapeutics Inc. (KPTI) Q3 2019 Results Earnings Conference Call November 04, 2019, 08:30 AM ET Company Participants Ian Karp - Vice President, Investor and Public Relations Michael Kauffman - Chief Executive Officer Sharon Shacham - President and Chief Scientific Off...
Camber Energy (NYSEMKT: CEI ) +53% . More news on: Camber Energy, Inc., Wright Medical Group N.V., Enlivex Therapeutics Ltd., Stocks on the move, Read more ...
The following slide deck was published by Karyopharm Therapeutics Inc. in conjunction with their 2019 Q3 earnings Read more ...
Karyopharm Therapeutics (NASDAQ: KPTI ): Q3 GAAP EPS of -$0.67 beats by $0.17 . Revenue of $13.15M (+5379.2% Y/Y) beats by $11.35M . Press Release More news on: Karyopharm Therapeutics Inc., Earnings news and commentary, Healthcare stocks news,
− XPOVIO Phase 2b STORM Study Results Published in The New England Journal of Medicine − − Achieved XPOVIO ® U.S. Net Product Sales of $12.8 Million with Over 500 Prescriptions Fulfilled as of September 30, 2019 – − Strengthened Balan...
NEWTON, Mass., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that it will report third quarter 2019 financial results on Monday, November 4, 2019. Karyopharm's management team will host a conference ...
Market Pulse Biotech and pharmaceutical groups have struggled immensely over the past two months as unique issues affecting the industry have become more dominant. The general market skittishness over rate policy and tariffs have also contributed to the woes. However, with the broader mark...
New York, New York--(Newsfile Corp. - September 20, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Karyopharm Therapeutics Inc. (NASDAQ: KPTI) ("Karyopharm" or the "Company") of the September 23, 2019 deadline to seek the role of lead plaintiff i...
News, Short Squeeze, Breakout and More Instantly...
Karyopharm Therapeutics Inc. Company Name:
KPTI Stock Symbol:
NASDAQ Market:
Karyopharm Therapeutics Inc. Website:
Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress PR Newswire – Achieves Second Quarter 2024 Total Revenue of $42.8 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $28.0 Million ; Positive Momentum e...
Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024 PR Newswire -- Conference Call Scheduled for Tuesday, August 6, 2024 , at 8:00 a.m. ET -- NEWTON, Mass. , July 31, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasd...
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates PR Newswire Long-Term Follow-Up Data Signal Promising Progression-Free S...